Agreement covers a variety of indications, including neuroscience and immunology.

Pharmacopeia and Organon entered into a alliance to discover, develop, and commercialize therapeutic products across a range of therapeutic indications, including neuroscience and immunology.

Pharmacopeia will receive an upfront payment of $15 million and additional payments in funding over the five-year term of the research work. Development will be primarily handled by Organon. Additionally, Pharmacopeia will receive milestone payments on any succesful candidate that Organon advances through clinical development, and up to double-digit royalties based on commercialization.

Pharmacopeia retains the option to co-develop and co-commercialize therapeutic candidates discovered through the alliance. Organon will hold exclusive rights on any compound that Pharmocopeia choses to not exercise this option.

Previous articleCytovance to Manufacture Bone Biologics’ Regeneration Therapy
Next articleElixir and Siena Biotech to Evaluate SIRT1 Inhibitors in Huntington’s Disease